CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, April 2015

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES

A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. Beckwith CG1, Kurth AE2, Bazerman LB3, et al. J Public Health (Oxf). 2015 Mar 2. pii: fdv023. [Epub ahead of print]

Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. Matsue Y1, Tsutsumi M1, Hayashi N1, et al. PLoS One. 2015 Mar 11;10(3):e0118744. doi: 10.1371/journal.pone.0118744. eCollection 2015.

Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine. Lalezari J1, Sullivan JG2, Varunok P3, et al. J Hepatol. 2015 Mar 31. pii: S0168-8278(15)00237-8. doi: 10.1016/j.jhep.2015.03.029. [Epub ahead of print]

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Bourlière M1, Bronowicki JP2, de Ledinghen V3, et al. Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Nelson DR1, Cooper JN, Lalezari JP, et al. Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.

Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease. Aida Y1, Abe H2, Tomita Y2, et al. J Gastrointestin Liver Dis. 2015 Mar;24(1):61-8. doi: 10.15403/jgld.2014.1121.yad.

Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. Sidharthan S1, Kohli A1, Sims Z1, Nelson A2, Osinusi A3, Masur H1, Kottilil S2. Clin Infect Dis. 2015 Mar 2. pii: civ170. [Epub ahead of print]

Ocular surface and tear parameters in patients with chronic hepatitis C at initial stages of hepatic fibrosis. Karaman Erdur S1, Kulac Karadeniz D, Kocabora MS, Ozsutcu M, Gulkilik IG, Demirci G, Eliacik M. Eye Contact Lens. 2015 Mar;41(2):117-20. doi: 10.1097/ICL.0000000000000079.

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Hepatitis C virus core protein induces epithelial-mesenchymal transition in human hepatocytes by upregulating E12/E47 levels. Tiwari I1, Yoon MH2, Park BJ2, Jang KL3. Cancer Lett. 2015 Jun 28;362(1):131-8. doi: 10.1016/j.canlet.2015.03.032. Epub 2015 Mar 27.

Hepatitis C virus structural proteins can exacerbate or ameliorate acetaminophen-induced liver injury in mice. Ramachandran A1, Lebofsky M, Yan HM, Weinman SA, Jaeschke H. Arch Toxicol. 2015 May;89(5):773-83. doi: 10.1007/s00204-015-1498-5. Epub 2015 Mar 6.

HCV Induces the Expression of Rubicon and UVRAG to Temporally Regulate the Maturation of Autophagosomes and Viral Replication. Wang L1, Tian Y1, Ou JH1. PLoS Pathog. 2015 Mar 25;11(3):e1004764. doi: 10.1371/journal.ppat.1004764. eCollection 2015.

Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5’UTR.

McCormick AL1, Macartney MJ2, Abdi-Abshir I2, Labbett W2, Smith C3, Irish D2, Webster DP2, Haque T2. J Clin Virol. 2015 May;66:56-9. doi: 10.1016/j.jcv.2015.03.006. Epub 2015

Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle. McGivern DR1, Masaki T2, Lovell W2, Hamlett C3, Saalau-Bethell S3, Graham B3. J Virol. 2015 Mar 4. pii: JVI.03188-14. [Epub ahead of print]

Dynamic Interaction of Stress Granule, DDX3X and IKK-α Mediates Multiple Functions in Hepatitis C Virus Infection. Pène V1, Li Q2, Sodroski C1, Hsu CS1, Liang TJ2. J Virol. 2015 Mar 4. pii: JVI.03197-14. [Epub ahead of print]

Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Serti E1, Chepa-Lotrea X1, Kim YJ2, et al. Gastroenterology. 2015 Mar 6. pii: S0016-5085(15)00309-1. doi: 10.1053/j.gastro.2015.03.004. [Epub ahead of print]

Genotype-specific differences in structural features of hepatitis C virus (HCV) p7 membrane protein. Kalita MM1, Griffin S2, Chou JJ3, Fischer WB4. Biochim Biophys Acta. 2015 Jun;1848(6):1383-92. doi: 10.1016/j.bbamem.2015.03.006. Epub 2015 Mar 13.

The transmitted/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C infection. Bull RA1, Leung P1, Gaudieri S2, et al. J Virol. 2015 Mar 4. pii: JVI.03717-14. [Epub ahead of print]

A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. Hiramine S1, Sugiyama M, Furusyo N, et al. J Gastroenterol. 2015 Mar 5. [Epub ahead of print]

HIV/HCV COINFECTION

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. Lo Re V 3rd1, Lynn K2, J Infect Dis. 2015 Mar 9. pii: jiv147. [Epub ahead of print]

Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan. Ogishi M1, Yotsuyanagi H1, Tsutsumi T1, et al. PLoS One. 2015 Mar 6;10(3):e0119145. doi: 10.1371/journal.pone.0119145. eCollection 2015.

CD4+ T cell-dependent reduction in hepatitis C virus-specific neutralizing antibody responses following coinfection with human immunodeficiency virus. Bailey JR1, Dowd KA2, Snider AE1, et al. J Infect Dis. 2015 Mar 9. pii: jiv139. [Epub ahead of print]

IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. Bertol BC1, Moreira S1, Garcia RF2, et al. Front Microbiol. 2015 Mar 4;6:153. doi: 10.3389/fmicb.2015.00153. eCollection 2015.

Immune Activation Response in Chronic HIV-Infected Patients: Influence of Hepatitis C Virus Coinfection. Márquez M1, Romero-Cores P1, Montes-Oca M1, et al. PLoS One. 2015 Mar 16;10(3):e0119568. doi: 10.1371/journal.pone.0119568. eCollection 2015.

COMPLEMENTARY AND ALTERNATIVE MEDICINE

Depsides: Lichen Metabolites Active against Hepatitis C Virus. Vu TH1, Le Lamer AC2, Lalli C1, et al. PLoS One. 2015 Mar 20;10(3):e0120405. doi: 10.1371/journal.pone.0120405. eCollection 2015.

EPIDEMIOLOGY, DIAGNOSTICS, AND MISCELLANEOUS WORKS

Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Sengupta S1, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Dig Dis Sci. 2015 Mar 6. [Epub ahead of print]

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Kirby BJ1, Symonds WT, Kearney BP, Mathias AA. Clin Pharmacokinet. 2015 Mar 31. [Epub ahead of print]

A Comparison of Liver Disease Mortality With HIV and Overdose Mortality Among Georgia Prisoners and Releasees: A 2-Decade Cohort Study of Prisoners Incarcerated in 1991. Spaulding AC1, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA. Am J Public Health. 2015 May;105(5):e51-7. doi: 10.2105/AJPH.2014.302546. Epub 2015 Mar 19.

Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics. Schaeffer S1, Khalili M1. Ann Hepatol. 2015 Mar-Apr;14(2):234-42.

Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs. Coffin PO1, Rowe C, Santos GM. Curr HIV/AIDS Rep. 2015 Mar;12(1):145-63. doi: 10.1007/s11904-014-0248-2.

Hepatitis C therapy: Looking toward interferon-sparing regimens. Au TH, Destache CJ, Vivekanandan R. J Am Pharm Assoc (2003). 2015 Mar 1;55(2):e72-86. doi: 10.1331/JAPhA.2015.15508.

Expanding capacity for hepatitis C treatment in the United States: team-based care and use of nonphysician providers. Kwong J1, Epstein R2. J Int Assoc Provid AIDS Care. 2015 Mar;14(2):112-5. doi: 10.1177/2325957414560065.

Genotype 1 of hepatitis C virus increases the risk of major depression: a 12-week prospective study. Cunha EC1, Behrensdorf MF2, Bavaresco V3, et al. Gen Hosp Psychiatry. 2015 Mar 31. pii: S0163-8343(15)00060-2. doi: 10.1016/j.genhosppsych.2015.03.016. [Epub ahead of print]

LIVER CANCER

Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Mikuriya Y1, Tashiro H, Kobayashi T, Kuroda S, Abe T, Hashimoto M, Ohdan H. Langenbecks Arch Surg. 2015 Mar 6. [Epub ahead of print]

A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Utsunomiya T1, Shimada M, Kudo M, et al. Ann Surg. 2015 Mar;261(3):513-20. doi: 10.1097/SLA.0000000000000821.

The “Macro” World of microRNAs in Hepatocellular Carcinoma. Sidhu K1, Kapoor NR1, Pandey V1, Kumar V1. Front Oncol. 2015 Mar 25;5:68. doi: 10.3389/fonc.2015.00068. eCollection 2015.

Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. Zhang SY1, Lin BD1, Li BR1. FEBS Open Bio. 2015 Mar 26;5:240-4. doi: 10.1016/j.fob.2015.03.010. eCollection 2015.

Plasma Protein Biomarkers of Hepatocellular Carcinoma in HCV-Infected Alcoholic Patients with Cirrhosis. Ferrín G1, Rodríguez-Perálvarez M2, Aguilar-Melero P3, et al. PLoS One. 2015 Mar 19;10(3):e0118527. doi: 10.1371/journal.pone.0118527. eCollection 2015.

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Park JW1, Chen M, Colombo M, et al. Liver Int. 2015 Mar 5. doi: 10.1111/liv.12818. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)